Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919803 | 0.80 | EHMT2 (0.45) | EHMT2EHMT1PGRHRH4 | |
| SCHEMBL4836307 | 0.76 | EHMT2 (0.47) | EHMT2EHMT1MEN1LMNAKMT2A | |
| SCHEMBL4874024 | 0.76 | HRH4 (0.57) | HRH4DRD2HTR7HTR6HTR2A | |
| SCHEMBL5553578 | 0.75 | RECQL (0.39) | MEN1LMNAKMT2AL3MBTL1HRH4 | |
| SCHEMBL5556168 | 0.72 | SMN1; SMN2 (0.41) | MEN1LMNAKMT2AL3MBTL1HRH4 | |
| SCHEMBL14454103 | 0.72 | BCL6 (0.46) | EHMT2EHMT1MEN1LMNAKMT2A | |
| SCHEMBL6608704 | 0.72 | UBE2M (0.36) | EHMT2EHMT1MEN1KMT2APGR | |
| SCHEMBL4829448 | 0.72 | EHMT2 (0.56) | EHMT2EHMT1MEN1LMNAKMT2A | |
| SCHEMBL5033412 | 0.71 | EHMT2 (0.38) | EHMT2EHMT1LMNAPGRHRH4 | |
| SCHEMBL6609401 | 0.71 | EHMT2 (0.41) | EHMT2EHMT1PGRHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EHMT2 2905/4885EHMT1 2811/4885MEN1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.